FUNDRAISING NEWS | December 06, 2024
Cambridge, MA-based investment firm Atlas Venture collected $450M in aggregate capital commitments on the final close of its fourteenth-generation flagship venture fund.
Atlas Venture Fund XIV will build on the long-running venture series by investing in early-stage biotech companies across disease areas, treatment modalities, and business models. The fund raised the same capital size as its predecessor Fund XIII, which closed in 2022 and has since exited portfolio companies Nimbus’ Tyk2 program, Versanis Bio, Aiolos Bio, and Mariana Oncology, while also launching 16 new biotech businesses. The venture firm said Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel, and Jason Rhodes were investing partners in Fund XIV.
Per Dakota data, Atlas manages approximately $3B in total assets.
